Phoenix Associates Land Syndicate (fka PBLSQ)

[jwilson2001florida]

Okay.. I know that this doesn't have anything to do with PBLS, but, I have a question and thought maybe some of you could help. I don't understand all the terminology, etc. with the stock market as I am very new to trading. I own this stock, and this news came out today, and all of the sudden the stock price dropped from like $3 range to $1 range... What does this mean, exactly... in "trading for dummies" language? Is this bad news where this stock will be worthless? Does this news seem to say that this stock will continue to fall with little hope of it rising again? HELP ME UNDERSTAND:

Raptor Pharmaceutical Corp. Announces $7.5 Million Securities OfferingDecember 18, 2009 8:45 AM ET advertisement

Article tools E-mail this article Print-friendly version Discuss this articleStocks mentioned in this articleRaptor Pharmaceutical Corp (RPTP) Stock Quote, Chart, News, Add to WatchlistRaptor Pharmaceuticals Corp (RPTP) Stock Quote, Chart, News, Add to WatchlistRecent investing newsEconomic Calendar: Dec. 21-Dec. 25($) Oracle Surges on Strong Earnings($) Look for Some Pickups on the Options SellingPermian Basin Royalty Trust Announces December Cash Distribution($) This ETF Answers the Call for Smartphones
All PR Newswire news

NOVATO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") RPTP, today announced that it has entered into definitive agreements with institutional investors to purchase 3,747,558 units for gross proceeds of approximately $7.5 million, before placement agent fees and offering expenses.

The offering is made pursuant to the Form S-3 shelf registration statement that was filed by Raptor with the Securities and Exchange Commission (the "SEC"). The offering is expected to close on or about December 22, 2009, subject to the satisfaction of customary closing conditions. Raptor intends to use the net proceeds from the offering for general corporate purposes, including activities related to further clinical development of DR Cysteamine and for other working capital and operational purposes.

The securities sold in this offering consist of one share of common stock and one warrant to purchase 0.5 of a share of common stock for a period of five years and one warrant to purchase 0.5 of a share of common stock for a period of 18 months. Both warrants have an exercise price of $2.45 per share of common stock and are exercisable starting with the date that is 180 days from the closing of the offering. The shares of common stock and warrants are immediately separable and will be issued separately.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. LTS, acted as the exclusive placement agent for this offering. CK Cooper & Co. acted as a selected dealer in this transaction.

The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission's website at http://www.sec.gov, or from Ladenburg Thalmann & Co. Inc., 520 Madison Avenue, 9th Floor, New York, New York 10022.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.